Wall Street equity research analysts covering Akebia Therapeutics have established a consensus average price target for AKBA sitting at approximately 3.75 dollars per share. This average target reflects projections provided by professional analysts tracking the firm's commercial-stage transition following the approval and rollout of its primary therapeutic product, Vafseo. While individual analyst forecasts vary from conservative estimates to more aggressive bullish targets, these figures indicate that professional researchers see substantial room for percentage growth compared to its prevailing market trading value, contingent upon consistent quarterly revenue expansion and effective cost management.